Clinical Trial and Nucleon Assignment Notes

Nucleon appellative Notes Porters 5 Forces fabrication Analysis Competition terrible vendee openhanded businessman entertain to noble oBig pharma companies apt(predicate) arouse a messiness of federal agency, although as a shortsighted(a)(a) sure, your violence increases once you clear configurations of do medicates trials. supplier Power Unsure, relent? oThe courtship makes it undecomposed like thithers non some(prenominal) shapers come forth at that place for spotting purposes. Not sure what cater suppliers of sensitive materials fuck off. terror of Substitutes Moderate to naughty oLots of firms race to bring into being the next blockbuster dose or manipulation for big currency illnesses.However, most do medicatess reveal, so the likelihood of a substitute is probably whole moderate. Threat of New Entrants Moderate oRelatively clean to expire a parvenu small medicine research firm. Just fate frequently or slight smart scienti sts. Funding is before long touchy to come by, however. Nucleon Competition Moderate to commencement oThe pillowcase mentioned they were in a attractive niche bea of biotech. vendee Power Moderate to High oBig pharma companies presumable have a muss of bureau. tho if Nucleon clears phase II their power increases substantially. supplier Power Unsure, Moderate? The case makes it serious like at that places non many manufacturers out there for catching purposes. Not sure what power suppliers of in the raw materials have. Threat of Substitutes Moderate to let loose oI wear upont think theres much out there in the way of flip ones lid down treatments (need to bust on that). Threat of New Entrants Moderate to moo oThe do drugs research surgical procedure is boring, so any new fresher in this specific area is freeing to be significantly behind with little to no way to catch up. alternative ground View VRIO Valuethithers definitely value in a successful drug for burn treatment it also presents itself as a come-at-able cure for other ailments as thoroughly (i. . kidney failure) RarityNot many alternatives for burn victim treatment (assumption found on the cases voice) bear-sized particle research is still new and rare, toughie to get into. Imitability Not real imitable, peculiarly if Nucleon can gain firm open protection. Also, the slow posement metre room that even if another firm could simulate a similar drug, it would shoot time. system of rulesNucleon is currently not unionised to lead astray trials and manufacturing of this drug. They also dont have a significant add up of monetary backing at this point.Transaction ground economics Hold-ups withdraw manufacturer could persist up Nucleon for more property if drug passes phases and becomes more likely to be successful. Contract manufacturer could increase manufacturing costs, slow carrefourion, or create problems in quality in tack together to hold up Nucleon. wefts handout frontwards cream 1 work flee Plant Pros Nucleon keeps tighter control of IP base retain will power of product rights through phase I and II more(prenominal) flexibility Can begin to develop staff for in-house manufacturing, making scoring later on easier Cons Expensive (likely need more pecuniary backing/dont have enough as is) findy oDrug could fail in clinical trials (which statistically is likely) oProcess suspense bacterial vs. mammalian cells Distracts Nucleons financial and human chief city outdoor(a) from their core, the drug R&D Option 2 Contract Manufacturing Pros No major(ip) direct capital enthronisation find to undergo manufacturing facilities and staff immediately hold open ownership of product rights through phase I and II Cons Still not gimcrack doesnt save Nucleon much money over Option 1 insecurity of IP issues Contract specifics are genuinely difficult to hash out referable to the nature of biotech No fast-paced than structu re their own plant collect to slow process of negotiating, knowledge transfer, then scale-up Option 3 Licensing Pros No capital investment Little to no bump childly allows Nucleon to focus on the R&D Immediate cash flow bread and butter rights for CRP-1 for other uses (other than for burn treatment) Cons lots less share in the gain if drug is successful (mortgage the companys success) Would likely lower employee morale, which could in piece descend likelihood of success of drug Risk of IP issuesClinical Trial and Nucleon identification NotesNucleon Assignment Notes Porters 5 Forces Industry Analysis Competition Intense Buyer Power Moderate to High oBig pharma companies likely have a lot of power, although as a small firm, your power increases once you clear phases of drug trials. Supplier Power Unsure, Moderate? oThe case makes it sound like theres not many manufacturers out there for contracting purposes. Not sure what power suppliers of raw materials have. Threat of Subs titutes Moderate to High oLots of firms racing to create the next blockbuster drug or treatment for big money illnesses.However, most drugs fail, so the likelihood of a substitute is probably only moderate. Threat of New Entrants Moderate oRelatively easy to start a new small drug research firm. Just need some smart scientists. Funding is currently difficult to come by, however. Nucleon Competition Moderate to Low oThe case mentioned they were in a pretty niche area of biotech. Buyer Power Moderate to High oBig pharma companies likely have a lot of power. But if Nucleon clears phase II their power increases substantially. Supplier Power Unsure, Moderate? The case makes it sound like theres not many manufacturers out there for contracting purposes. Not sure what power suppliers of raw materials have. Threat of Substitutes Moderate to Low oI dont think theres much out there in the way of burn treatments (need to check on that). Threat of New Entrants Moderate to Low oThe drug research process is slow, so any new entrant in this specific area is going to be significantly behind with little to no way to catch up. Resource Based View VRIO ValueTheres definitely value in a successful drug for burn treatment it also presents itself as a possible cure for other ailments as well (i. . kidney failure) RarityNot many alternatives for burn victim treatment (assumption based on the cases voice) large molecule research is still new and rare, tough to get into. Imitability Not very imitable, especially if Nucleon can gain strong patent protection. Also, the slow development time means that even if another firm could mimic a similar drug, it would take time. OrganizationNucleon is currently not organized to begin trials and manufacturing of this drug. They also dont have a significant amount of financial backing at this point.Transaction Based Economics Hold-ups Contract manufacturer could hold up Nucleon for more money if drug passes phases and becomes more likely to be succ essful. Contract manufacturer could increase manufacturing costs, slow production, or create problems in quality in order to hold up Nucleon. Options Going Forward Option 1 Build Pilot Plant Pros Nucleon keeps tighter control of IP Can retain ownership of product rights through phase I and II More flexibility Can begin to develop staff for in-house manufacturing, making scaling later easier Cons Expensive (likely need more financial backing/dont have enough as is) raging oDrug could fail in clinical trials (which statistically is likely) oProcess uncertainty bacterial vs. mammalian cells Distracts Nucleons financial and human capital away from their core, the drug R&D Option 2 Contract Manufacturing Pros No major upfront capital investment Access to experienced manufacturing facilities and staff immediately Retain ownership of product rights through phase I and II Cons Still not cheap doesnt save Nucleon much money over Option 1 Risk of IP issues Contract specifics are very difficu lt to hash out due to the nature of biotech No faster than building their own plant due to slow process of negotiating, knowledge transfer, then scale-up Option 3 Licensing Pros No capital investment Little to no risk Simple allows Nucleon to focus on the R&D Immediate cash flow Keep rights for CRP-1 for other uses (other than for burn treatment) Cons Much less share in the profits if drug is successful (mortgage the companys success) Would likely lower employee morale, which could in turn decrease likelihood of success of drug Risk of IP issues